Korean J Urol.  2013 May;54(5):283-288. 10.4111/kju.2013.54.5.283.

Small Renal Masses: Surgery or Surveillance

• Hwang EC
• Yu HS
• Kwon DD

• KMID: 2061508
• DOI: http://doi.org/10.4111/kju.2013.54.5.283

Abstract

The incidence of kidney cancer has been rising over the past two decades, especially in cases in which the disease is localized and small in size (<4 cm). This rise is mainly due to the widespread use of routine abdominal imaging such as ultrasonography, computed tomography, and magnetic resonance imaging. Early detection was initially heralded as an opportunity to cure an otherwise lethal disease. However, despite increasing rates of renal surgery in parallel to this trend, mortality rates from renal cell carcinoma have remained relatively unchanged. Moreover, data suggest that a substantial proportion of small renal masses are benign. As a result, the management of small renal masses has continued to evolve along two basic themes: it has become less radical and less invasive. These shifts are in part a reflection of an improved understanding that the biology of incidentally discovered renal cell carcinoma may be more indolent than previously thought. However, not all small renal masses are indolent, and de novo metastatic disease can develop at the initial presentation. Therefore, it is with this background of clinical uncertainty and biological heterogeneity that clinicians must interpret the benefits and disadvantages of various clinical approaches to small renal masses.

Keyword

Kidney neoplasms; Nephrectomy; Watchful waiting

MeSH Terms

Biology
Carcinoma, Renal Cell
Incidence
Kidney Neoplasms
Magnetic Resonance Imaging
Nephrectomy
Population Characteristics
Uncertainty
Watchful Waiting

Reference

1. Adami HO, Hunter DJ, Trichopoulos D. Textbook of cancer epidemiology. 2002. New York: Oxford University Press.

2. National Cancer Information Center [Internet]. c2012. cited 2013 Mar 19. Goyang: National Cancer Information Center;Available from: http://www.cancer.go.kr.

3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011. 61:69–90.

4. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998. 51:203–205.

5. Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice: small renal mass. N Engl J Med. 2010. 362:624–634.

6. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003. 170(6 Pt 1):2217–2220.

7. Russo P. Should elective partial nephrectomy be performed for renal cell carcinoma >4 cm in size? Nat Clin Pract Urol. 2008. 5:482–483.

8. Thomas AA, Aron M, Hernandez AV, Lane BR, Gill IS. Laparoscopic partial nephrectomy in octogenarians. Urology. 2009. 74:1042–1046.

9. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006. 98:1331–1334.

10. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999. 162:1930–1933.

11. Abouassaly R, Alibhai SM, Tomlinson G, Timilshina N, Finelli A. Unintended consequences of laparoscopic surgery on partial nephrectomy for kidney cancer. J Urol. 2010. 183:467–472.

12. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006. 7:735–740.

13. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008. 179:468–471.

14. Thompson RH, Siddiqui S, Lohse CM, Leibovich BC, Russo P, Blute ML. Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol. 2009. 182:2601–2606.

15. Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS. Urologic Diseases in America Project. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer. 2008. 112:511–520.

16. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors: is there a difference in mortality and cardiovascular outcomes? J Urol. 2009. 181:55–61.

17. Van Poppel H, Becker F, Cadeddu JA, Gill IS, Janetschek G, Jewett MA, et al. Treatment of localised renal cell carcinoma. Eur Urol. 2011. 60:662–672.

18. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol. 2008. 180:505–508.

19. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006. 175:425–431.

20. Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DY, Uzzo RG. Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer. 2008. 112:1051–1057.

21. Volpe A. The role of surveillance in the management of small renal masses. ScientificWorldJournal. 2007. 7:860–868.

22. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma: a meta-analysis and review. J Urol. 2008. 179:1227–1233.

23. Duchene DA, Lotan Y, Cadeddu JA, Sagalowsky AI, Koeneman KS. Histopathology of surgically managed renal tumors: analysis of a contemporary series. Urology. 2003. 62:827–830.

24. Ramirez ML, Evans CP. Current management of small renal masses. Can J Urol. 2007. 14:Suppl 1. 39–47.

25. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol. 2000. 163:730–736.

26. Schlomer B, Figenshau RS, Yan Y, Venkatesh R, Bhayani SB. Pathological features of renal neoplasms classified by size and symptomatology. J Urol. 2006. 176(4 Pt 1):1317–1320.

27. DeRoche T, Walker E, Magi-Galluzzi C, Zhou M. Pathologic characteristics of solitary small renal masses: can they be predicted by preoperative clinical parameters? Am J Clin Pathol. 2008. 130:560–564.

28. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. 2000. 163:426–430.

29. Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007. 177:849–853.

30. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009. 182:1271–1279.

31. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, et al. NCCN clinical practice guidelines in oncology: kidney cancer. 2013 [Internet]. c2013. cited 2013 Mar 19. Fort Wathington: NCCN;Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.

32. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010. 58:398–406.

33. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007. 51:1606–1615.

34. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000. 75:1236–1242.

35. Zini L, Patard JJ, Capitanio U, Crepel M, de La Taille A, Tostain J, et al. Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma. BJU Int. 2009. 103:894–898.

36. Klarenbach S, Moore RB, Chapman DW, Dong J, Braam B. Adverse renal outcomes in subjects undergoing nephrectomy for renal tumors: a population-based analysis. Eur Urol. 2011. 59:333–339.

37. Simhan J, Smaldone MC, Tsai KJ, Canter DJ, Li T, Kutikov A, et al. Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur Urol. 2011. 60:724–730.

38. Hillyer SP, Autorino R, Spana G, Guillotreau J, Stein RJ, Haber GP, et al. Perioperative outcomes of robotic-assisted partial nephrectomy in elderly patients: a matched-cohort study. Urology. 2012. 79:1063–1067.

39. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Groupe Français d'Immunothérapie. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med. 1998. 338:1272–1278.

40. Kunkle DA, Haas NB, Uzzo RG. Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep. 2007. 8:19–30.

41. Silverman SG, Gan YU, Mortele KJ, Tuncali K, Cibas ES. Renal masses in the adult patient: the role of percutaneous biopsy. Radiology. 2006. 240:6–22.

42. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy: a renaissance? J Urol. 2008. 179:20–27.

43. Rybicki FJ, Shu KM, Cibas ES, Fielding JR, vanSonnenberg E, Silverman SG. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. AJR Am J Roentgenol. 2003. 180:1281–1287.

44. Remzi M, Katzenbeisser D, Waldert M, Klingler HC, Susani M, Memarsadeghi M, et al. Renal tumour size measured radiologically before surgery is an unreliable variable for predicting histopathological features: benign tumours are not necessarily small. BJU Int. 2007. 99:1002–1006.

45. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009. 181:1020–1027.

46. Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG. Predicting growth of solid renal masses under active surveillance. Urol Oncol. 2008. 26:555–559.

47. Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, et al. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol. 2008. 179:1719–1726.

48. Jeon HG, Lee SR, Kim KH, Oh YT, Cho NH, Rha KH, et al. Benign lesions after partial nephrectomy for presumed renal cell carcinoma in masses 4 cm or less: prevalence and predictors in Korean patients. Urology. 2010. 76:574–579.

49. Lee SH, Park SU, Rha KH, Choi YD, Hong SJ, Yang SC, et al. Trends in the incidence of benign pathological lesions at partial nephrectomy for presumed renal cell carcinoma in renal masses on preoperative computed tomography imaging: a single institute experience with 290 consecutive patients. Int J Urol. 2010. 17:512–516.

50. Jeldres C, Sun M, Liberman D, Lughezzani G, de la Taille A, Tostain J, et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol. 2009. 182:2585–2589.

51. Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007. 178:429–434.

52. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007. 178:2359–2364.

53. Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol. 2009. 182:2274–2278.

54. Kunkle DA, Crispen PL, Li T, Uzzo RG. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol. 2007. 177:1692–1696.

55. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010. 116:3119–3126.

56. Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011. 60:39–44.

57. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007. 109:1763–1768.

58. Jacobs BL, Tan HJ, Montgomery JS, Weizer AZ, Wood DP, Miller DC, et al. Understanding criteria for surveillance of patients with a small renal mass. Urology. 2012. 79:1027–1032.

59. Abouassaly R, Yang S, Finelli A, Kulkarni GS, Alibhai SM. What is the best treatment strategy for incidentally detected small renal masses? A decision analysis. BJU Int. 2011. 108(8 Pt 2):E223–E231.